Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products.
The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes.
In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions.
Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health.
The company has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 18, 25 | -548.78 Decreased by -394.09% | - |
| Aug 14, 25 | -390.17 Decreased by -9.21 K% | - |
| May 19, 25 | -8.12 Increased by +77.96% | - |
| Mar 31, 25 | -100.70 Increased by +93.16% | - |
| Nov 12, 24 | -111.07 Decreased by -131.39% | - |
| Aug 19, 24 | -4.19 Decreased by -355.29% | - |
| Apr 16, 24 | -36.82 Decreased by -2.71 K% | -29.81 Decreased by -23.52% |
| Feb 28, 24 | -1.47 K Decreased by -75.04 K% | -1.19 K Decreased by -23.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 425.00 Decreased by -86.61% | -4.70 M Increased by +10.04% | Decreased by -1.11 M% Decreased by -572.03% |
| Sep 30, 25 | 748.00 Decreased by -89.09% | -24.05 M Decreased by -246.45% | Decreased by -3.21 M% Decreased by -3.07 K% |
| Jun 30, 25 | 1.00 K Decreased by -97.73% | -7.26 M Increased by +3.88% | Decreased by -722.79 K% Decreased by -4.14 K% |
| Mar 31, 25 | 1.02 K Decreased by -98.72% | -5.71 M Increased by +61.23% | Decreased by -560.93 K% Decreased by -2.93 K% |
| Dec 31, 24 | 3.17 K Decreased by -96.09% | -5.23 M Increased by +52.35% | Decreased by -164.62 K% Decreased by -1.12 K% |
| Sep 30, 24 | 6.85 K Decreased by -94.49% | -6.94 M Increased by +28.79% | Decreased by -101.26 K% Decreased by -1.19 K% |
| Jun 30, 24 | 44.28 K Decreased by -79.96% | -7.55 M Decreased by -32.87% | Decreased by -17.05 K% Decreased by -563.14% |
| Mar 31, 24 | 79.68 K Decreased by -63.52% | -14.73 M Decreased by -146.11% | Decreased by -18.49 K% Decreased by -574.63% |